OCTREOSCAN Side Effects

6703652-6 | Haemoglobin Abnormal
on Apr 19, 2010 Male patient from UNITED STATES , 48 years of age, was diagnosed with carcinoid tumour of the gastrointestinal tract and was treated with Octreoscan (View Usage). Patient experienced the following unwanted or unexpected effects: haemoglobin abnormal. Octreoscan dosage: Unk.

6703651-4 | Blood Bilirubin Abnormal, Metastases To Liver
Patient was taking Octreoscan (View Usage). Patient had the following side effects: blood bilirubin abnormal, metastases to liver on Apr 19, 2010 from UNITED STATES Additional patient health information: Female patient , 38 years of age, was diagnosed with carcinoid tumour of the gastrointestinal tract and. Octreoscan dosage: 180 Mci.

6703646-0 | Blood Bilirubin Abnormal, Blood Creatinine Abnormal, Haemoglobin Abnormal
Adverse event was reported on Apr 19, 2010 by a Female patient taking Octreoscan (View Usage) (Dosage: Unk) was diagnosed with carcinoid tumour of the gastrointestinal tract and. Location: UNITED STATES , 51 years of age, After Octreoscan was administered, patient had the following side effects: blood bilirubin abnormal, blood creatinine abnormal, haemoglobin abnormal.

6703645-9 | Blood Bilirubin Abnormal, Haemoglobin Abnormal, Nausea, Platelet Disorder, White Blood Cell Disorder
on Apr 19, 2010 Female patient from UNITED STATES , 67 years of age, was diagnosed with carcinoid tumour of the gastrointestinal tract and was treated with Octreoscan (View Usage). Patient experienced the following unwanted or unexpected effects: blood bilirubin abnormal, haemoglobin abnormal, nausea (What is nausea?), platelet disorder, white blood cell disorder. Octreoscan dosage: Unk.


6703644-7 | Blood Creatinine Abnormal, Haematotoxicity, Respiratory Failure, White Blood Cell Disorder
on Apr 19, 2010 Female patient from UNITED STATES , 65 years of age, was diagnosed with somatostatin receptor scan and was treated with Octreoscan (View Usage). Patient had the following side effects: blood creatinine abnormal, haematotoxicity, respiratory failure, white blood cell disorder. Octreoscan dosage: 6 Mci, Single. During the same period patient was treated with INDIUM (111 IN) (180 Mci, Single) (View Indium (111 In) Review and Indium (111 In) Label ).

6703643-5 | Haemoglobin Abnormal, Platelet Disorder, White Blood Cell Disorder
Patient was taking Octreoscan (View Usage). After Octreoscan was administered, patient had the following side effects: haemoglobin abnormal, platelet disorder, white blood cell disorder on Apr 19, 2010 from UNITED STATES Additional patient health information: Male patient , 62 years of age, was diagnosed with carcinoid tumour of the gastrointestinal tract and. Octreoscan dosage: Unk.

6703642-3 | Blood Bilirubin Abnormal, Haemoglobin Abnormal, Nausea, Platelet Disorder, White Blood Cell Disorder
Adverse event was reported on Apr 19, 2010 by a Male patient taking Octreoscan (View Usage) (Dosage: Unk) was diagnosed with carcinoid tumour of the gastrointestinal tract and. Location: UNITED STATES , 45 years of age, Patient experienced the following unwanted or unexpected effects: blood bilirubin abnormal, haemoglobin abnormal, nausea (What is nausea?), platelet disorder, white blood cell disorder.

6703641-1 | Haematotoxicity, Platelet Disorder
on Apr 19, 2010 Female patient from UNITED STATES , 58 years of age, was diagnosed with somatostatin receptor scan and was treated with Octreoscan (View Usage). Patient had the following side effects: haematotoxicity, platelet disorder. Octreoscan dosage: 6 Mci, Single. During the same period patient was treated with INDIUM (111 IN) (180 Mci, Single) (View Indium (111 In) Review and Indium (111 In) Label ).

6703640-X | Blood Bilirubin Abnormal, Condition Aggravated, Haematotoxicity, Neurotoxicity, Platelet Toxicity
on Apr 19, 2010 Male patient from UNITED STATES , 56 years of age, was diagnosed with somatostatin receptor scan and was treated with Octreoscan (View Usage). After Octreoscan was administered, patient had the following side effects: blood bilirubin abnormal, condition aggravated, haematotoxicity, neurotoxicity, platelet toxicity. Octreoscan dosage: 6 Mci, Single. During the same period patient was treated with INDIUM (111 IN) (180 Mci, Single) (View Indium (111 In) Review and Indium (111 In) Label ).

6703639-3 | Haematotoxicity
Patient was taking Octreoscan (View Usage). Patient experienced the following unwanted or unexpected effects: haematotoxicity on Apr 19, 2010 from UNITED STATES Additional patient health information: Female patient , 54 years of age, was diagnosed with somatostatin receptor scan and. Octreoscan dosage: 6 Mci, Single. During the same period patient was treated with INDIUM (111 IN) (180 Mci, Single) (View Indium (111 In) Review and Indium (111 In) Label ).

6703638-1 | Haemoglobin Abnormal, White Blood Cell Disorder
Adverse event was reported on Apr 19, 2010 by a Male patient taking Octreoscan (View Usage) (Dosage: Unk) was diagnosed with carcinoid tumour of the gastrointestinal tract and. Location: UNITED STATES , 69 years of age, Patient had the following side effects: haemoglobin abnormal, white blood cell disorder.

6703637-X | Haemoglobin Abnormal, Ileus
on Apr 19, 2010 Female patient from UNITED STATES , 52 years of age, was diagnosed with carcinoid tumour of the gastrointestinal tract and was treated with Octreoscan (View Usage). After Octreoscan was administered, patient had the following side effects: haemoglobin abnormal, ileus. Octreoscan dosage: Unk.

6703636-8 | Haematotoxicity, Neurotoxicity, Platelet Toxicity
on Apr 19, 2010 Male patient from UNITED STATES , 42 years of age, was diagnosed with somatostatin receptor scan and was treated with Octreoscan (View Usage). Patient experienced the following unwanted or unexpected effects: haematotoxicity, neurotoxicity, platelet toxicity. Octreoscan dosage: 6 Mci, Single. During the same period patient was treated with INDIUM (111 IN) (180 Mci, Single) (View Indium (111 In) Review and Indium (111 In) Label ), INTERFERON (Unk) (View Interferon Review and Interferon Label ).

6703635-6 | Blood Creatinine Abnormal, Haemoglobin Abnormal, Platelet Disorder
Patient was taking Octreoscan (View Usage). Patient had the following side effects: blood creatinine abnormal, haemoglobin abnormal, platelet disorder on Apr 19, 2010 from UNITED STATES Additional patient health information: Male patient , 65 years of age, was diagnosed with carcinoid tumour of the gastrointestinal tract and. Octreoscan dosage: Unk.

6703634-4 | Haemoglobin Abnormal, Infection
Adverse event was reported on Apr 19, 2010 by a Male patient taking Octreoscan (View Usage) (Dosage: Unk) was diagnosed with carcinoid tumour of the gastrointestinal tract and. Location: UNITED STATES , 47 years of age, After Octreoscan was administered, patient had the following side effects: haemoglobin abnormal, infection (What is infection?).

6703633-2 | Blood Creatinine Abnormal, Haemoglobin Abnormal
on Apr 19, 2010 Female patient from UNITED STATES , 69 years of age, was diagnosed with carcinoid tumour of the gastrointestinal tract and was treated with Octreoscan (View Usage). Patient experienced the following unwanted or unexpected effects: blood creatinine abnormal, haemoglobin abnormal. Octreoscan dosage: Unk.

6703632-0 | Haemoglobin Abnormal, Platelet Disorder, Therapeutic Agent Toxicity
on Apr 19, 2010 Male patient from UNITED STATES , 55 years of age, was diagnosed with carcinoid tumour of the gastrointestinal tract and was treated with Octreoscan (View Usage). Patient had the following side effects: haemoglobin abnormal, platelet disorder, therapeutic agent toxicity. Octreoscan dosage: Unk.

6703631-9 | Haemoglobin Abnormal, Platelet Disorder
Patient was taking Octreoscan (View Usage). After Octreoscan was administered, patient had the following side effects: haemoglobin abnormal, platelet disorder on Apr 19, 2010 from UNITED STATES Additional patient health information: Female patient , 48 years of age, was diagnosed with carcinoid tumour of the gastrointestinal tract and. Octreoscan dosage: 180 Mci.

6703630-7 | Blood Bilirubin Abnormal, Haemoglobin Abnormal, Platelet Disorder
Adverse event was reported on Apr 19, 2010 by a Female patient taking Octreoscan (View Usage) (Dosage: Unk) was diagnosed with carcinoid tumour of the gastrointestinal tract and. Location: UNITED STATES , 53 years of age, Patient experienced the following unwanted or unexpected effects: blood bilirubin abnormal, haemoglobin abnormal, platelet disorder.

6703629-0 | Haemoglobin Abnormal, Platelet Disorder
on Apr 19, 2010 Male patient from UNITED STATES , 72 years of age, was diagnosed with carcinoid tumour of the gastrointestinal tract and was treated with Octreoscan (View Usage). Patient had the following side effects: haemoglobin abnormal, platelet disorder. Octreoscan dosage: Unk.

6703628-9 | Blood Bilirubin Abnormal, Haemoglobin Abnormal, Platelet Disorder, White Blood Cell Disorder
on Apr 19, 2010 Male patient from UNITED STATES , 56 years of age, was diagnosed with carcinoid tumour of the gastrointestinal tract and was treated with Octreoscan (View Usage). After Octreoscan was administered, patient had the following side effects: blood bilirubin abnormal, haemoglobin abnormal, platelet disorder, white blood cell disorder. Octreoscan dosage: Unk.

6698036-3 | Acute Myeloid Leukaemia, Neoplasm Progression
Patient was taking Octreoscan (View Usage). Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia, neoplasm progression on Apr 17, 2010 from NETHERLANDS Additional patient health information: Female patient , 36 years of age, was diagnosed with neuroendocrine tumour and. Octreoscan dosage: 108.72 Gbq, Unk.

6698035-1 | Myelodysplastic Syndrome, Neoplasm Progression
Adverse event was reported on Apr 17, 2010 by a Female patient taking Octreoscan (View Usage) (Dosage: 143.35 Gbq, Unk) was diagnosed with neuroendocrine tumour and. Location: NETHERLANDS , 65 years of age, Patient had the following side effects: myelodysplastic syndrome, neoplasm progression.

6698034-X | Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Neoplasm Progression
on Apr 17, 2010 Female patient from NETHERLANDS , 62 years of age, was diagnosed with carcinoid tumour and was treated with Octreoscan (View Usage). After Octreoscan was administered, patient had the following side effects: acute myeloid leukaemia, myelodysplastic syndrome, neoplasm progression. Octreoscan dosage: 106.01 Gbq, Unk.

6698033-8 | Thrombocytopenia
on Apr 17, 2010 Male patient from NETHERLANDS , 67 years of age, was diagnosed with carcinoid tumour and was treated with Octreoscan (View Usage). Patient experienced the following unwanted or unexpected effects: thrombocytopenia. Octreoscan dosage: 57.99 Gbq, Unk.

6696110-9 | Thrombocytopenia
Patient was taking Octreoscan (View Usage). Patient had the following side effects: thrombocytopenia on Apr 17, 2010 from NETHERLANDS Additional patient health information: Female patient , 47 years of age, was diagnosed with gastrinoma and. Octreoscan dosage: 10 Gbq.

6449858-5 | Disease Progression, Disseminated Intravascular Coagulation, Lymphopenia, Therapeutic Response Decreased
Adverse event was reported on Nov 09, 2009 by a Male patient taking Octreoscan (View Usage) (Dosage: 5.3 - 7.8 Gbq Via Infusion Pump Over 20 Minutes) was diagnosed with carcinoid tumour and. Location: AUSTRALIA , 56 years of age, After Octreoscan was administered, patient had the following side effects: disease progression, disseminated intravascular coagulation, lymphopenia, therapeutic response decreased. During the same period patient was treated with 5 FLUOROURACIL /00098801/ (200 Mg/m2, Qd Via Continuous Ambulatory Iv Pump) (View 5-fluorouracil /00098801/ Review and 5-fluorouracil /00098801/ Label ), 5 FLUOROURACIL /00098801/ (200 Mg/m2, Qd Via Continuous Ambulatory Iv Pump) (View 5-fluorouracil /00098801/ Review and 5-fluorouracil /00098801/ Label ), 5 FLUOROURACIL /00098801/ (200 Mg/m2, Qd Via Continuous Ambulatory Iv Pump) (View 5-fluorouracil /00098801/ Review and 5-fluorouracil /00098801/ Label ), NORMAL SALINE (View Normal Saline Review and Normal Saline Label ).

6449857-3 | Disease Progression, Lymphopenia
on Nov 09, 2009 Male patient from AUSTRALIA , 60 years of age, was diagnosed with carcinoid tumour and was treated with Octreoscan (View Usage). Patient experienced the following unwanted or unexpected effects: disease progression, lymphopenia. Octreoscan dosage: 5.3 - 7.8 Gbq Via Infusion Pump Over 20 Minutes. During the same period patient was treated with 5 FLUOROURACIL /00098801/ (200 Mg/m2, Qd Via Continuous Ambulatory Iv Pump) (View 5-fluorouracil /00098801/ Review and 5-fluorouracil /00098801/ Label ), 5 FLUOROURACIL /00098801/ (200 Mg/m2, Qd Via Continuous Ambulatory Iv Pump) (View 5-fluorouracil /00098801/ Review and 5-fluorouracil /00098801/ Label ), 5 FLUOROURACIL /00098801/ (200 Mg/m2, Qd Via Continuous Ambulatory Iv Pump) (View 5-fluorouracil /00098801/ Review and 5-fluorouracil /00098801/ Label ), NORMAL SALINE (View Normal Saline Review and Normal Saline Label ).

6449853-6 | Disease Progression, Lymphopenia
on Nov 09, 2009 Male patient from AUSTRALIA , 75 years of age, was diagnosed with carcinoid tumour and was treated with Octreoscan (View Usage). Patient had the following side effects: disease progression, lymphopenia. Octreoscan dosage: 5.3 - 7.8 Gbq Via Infusion Pump Over 20 Minutes. During the same period patient was treated with 5 FLUOROURACIL /00098801/ (200 Mg/m2, Qd Via Continuous Ambulatory Iv Pump) (View 5-fluorouracil /00098801/ Review and 5-fluorouracil /00098801/ Label ), 5 FLUOROURACIL /00098801/ (200 Mg/m2, Qd Via Continuous Ambulatory Iv Pump) (View 5-fluorouracil /00098801/ Review and 5-fluorouracil /00098801/ Label ), 5 FLUOROURACIL /00098801/ (200 Mg/m2, Qd Via Continuous Ambulatory Iv Pump) (View 5-fluorouracil /00098801/ Review and 5-fluorouracil /00098801/ Label ), NORMAL SALINE (View Normal Saline Review and Normal Saline Label ).

6449485-X | Disease Progression, Mucosal Inflammation, Nausea
Patient was taking Octreoscan (View Usage). After Octreoscan was administered, patient had the following side effects: disease progression, mucosal inflammation, nausea (What is nausea?) on Nov 09, 2009 from AUSTRALIA Additional patient health information: Female patient , 52 years of age, was diagnosed with carcinoid tumour and. Octreoscan dosage: 5.3 - 7.8 Gbq Via Infusion Pump Over 20 Minutes. During the same period patient was treated with 5 FLUOROURACIL /00098801/ (200 Mg/m2, Qd Via Continuous Ambulatory Iv Pump) (View 5-fluorouracil /00098801/ Review and 5-fluorouracil /00098801/ Label ), 5 FLUOROURACIL /00098801/ (200 Mg/m2, Qd Via Continuous Ambulatory Iv Pump) (View 5-fluorouracil /00098801/ Review and 5-fluorouracil /00098801/ Label ), 5 FLUOROURACIL /00098801/ (200 Mg/m2, Qd Via Continuous Ambulatory Iv Pump) (View 5-fluorouracil /00098801/ Review and 5-fluorouracil /00098801/ Label ), NORMAL SALINE (View Normal Saline Review and Normal Saline Label ).

6356261-5 | Haematotoxicity, Neurotoxicity, Platelet Toxicity
Adverse event was reported on Sep 02, 2009 by a Male patient taking Octreoscan (View Usage) (Dosage: 6 Mci, Single) was diagnosed with somatostatin receptor scan and. Location: UNITED STATES , 42 years of age, Patient experienced the following unwanted or unexpected effects: haematotoxicity, neurotoxicity, platelet toxicity. During the same period patient was treated with INDIUM (111 IN) (180 Mci, Single) (View Indium (111 In) Review and Indium (111 In) Label ), INTERFERON (Unk) (View Interferon Review and Interferon Label ).

6356260-3 | Condition Aggravated, Haematotoxicity, Neurotoxicity, Platelet Toxicity
on Sep 02, 2009 Male patient from UNITED STATES , 56 years of age, was diagnosed with somatostatin receptor scan and was treated with Octreoscan (View Usage). Patient had the following side effects: condition aggravated, haematotoxicity, neurotoxicity, platelet toxicity. Octreoscan dosage: 6 Mci, Single. During the same period patient was treated with INDIUM (111 IN) (180 Mci, Single) (View Indium (111 In) Review and Indium (111 In) Label ).

6356258-5 | Condition Aggravated, Platelet Toxicity
on Sep 02, 2009 Female patient from UNITED STATES , 22 years of age, was diagnosed with somatostatin receptor scan and was treated with Octreoscan (View Usage). After Octreoscan was administered, patient had the following side effects: condition aggravated, platelet toxicity. Octreoscan dosage: 6 Mci, Single. During the same period patient was treated with INDIUM (111 IN) (180 Mci, Single) (View Indium (111 In) Review and Indium (111 In) Label ).

6356257-3 | Haematotoxicity, Platelet Toxicity
Patient was taking Octreoscan (View Usage). Patient experienced the following unwanted or unexpected effects: haematotoxicity, platelet toxicity on Sep 02, 2009 from UNITED STATES Additional patient health information: Male patient , 40 years of age, was diagnosed with somatostatin receptor scan and. Octreoscan dosage: 6 Mci, Single. During the same period patient was treated with INDIUM (111 IN) (180 Mci, Single) (View Indium (111 In) Review and Indium (111 In) Label ).

6356256-1 | Haematotoxicity, Platelet Toxicity
Adverse event was reported on Sep 02, 2009 by a Female patient taking Octreoscan (View Usage) (Dosage: 6 Mci, Single) was diagnosed with somatostatin receptor scan and. Location: UNITED STATES , 53 years of age, Patient had the following side effects: haematotoxicity, platelet toxicity. During the same period patient was treated with INDIUM (111 IN) (180 Mci, Single) (View Indium (111 In) Review and Indium (111 In) Label ).

6220826-1 | Accidental Exposure
on Apr 27, 2009 Female patient from UNITED STATES , weighting 125.0 lb, was treated with Octreoscan (View Usage). After Octreoscan was administered, patient had the following side effects: accidental exposure. Octreoscan dosage: Unk.

6220824-8 | Abdominal Pain, Asthenia, Diarrhoea, Flatulence, Hyperhidrosis, Nausea, Pyrexia
on Apr 22, 2009 Female patient from UNITED STATES , 41 years of age, was diagnosed with somatostatin receptor scan, thyroid disorder, hypertension, helicobacter gastritis, migraine (What is migraine?), asthma (What is asthma?) and was treated with Octreoscan (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), asthenia, diarrhoea, flatulence, hyperhidrosis, nausea (What is nausea?), pyrexia. Octreoscan dosage: 6.5 Mci, Single. During the same period patient was treated with SYNTHROID (Unk) (View Synthroid Review and Synthroid Label ), COREG (Unk) (View Coreg Review and Coreg Label ), PRILOSEC (Unk) (View Prilosec Review and Prilosec Label ), PYLERICA (Unk) (View Pylerica Review and Pylerica Label ), XYZAL (Unk) (View Xyzal Review and Xyzal Label ), TOPAMAX (Unk) (View Topamax Review and Topamax Label ), SINGULAIR (Unk) (View Singulair Review and Singulair Label ), MULTI VITAMINS (Unk) (View Multi-vitamins Review and Multi-vitamins Label ).

6220127-1 | Abdominal Pain, Asthenia, Diarrhoea, Flatulence, Hyperhidrosis, Nausea, Pyrexia
Patient was taking Octreoscan (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), asthenia, diarrhoea, flatulence, hyperhidrosis, nausea (What is nausea?), pyrexia on Apr 22, 2009 from UNITED STATES Additional patient health information: Female patient , 41 years of age, was diagnosed with somatostatin receptor scan, thyroid disorder, hypertension, helicobacter gastritis, migraine (What is migraine?), asthma (What is asthma?) and. Octreoscan dosage: 6.5 Mci, Single. During the same period patient was treated with SYNTHROID (Unk) (View Synthroid Review and Synthroid Label ), COREG (Unk) (View Coreg Review and Coreg Label ), PRILOSEC (Unk) (View Prilosec Review and Prilosec Label ), PYLERICA (Unk) (View Pylerica Review and Pylerica Label ), XYZAL (Unk) (View Xyzal Review and Xyzal Label ), TOPAMAX (Unk) (View Topamax Review and Topamax Label ), SINGULAIR (Unk) (View Singulair Review and Singulair Label ), MULTI VITAMINS (Unk) (View Multi-vitamins Review and Multi-vitamins Label ).

6220126-X | Accidental Exposure
Adverse event was reported on Apr 27, 2009 by a Female patient taking Octreoscan (View Usage) (Dosage: Unk) . Location: UNITED STATES , weighting 125.0 lb, After Octreoscan was administered, patient had the following side effects: accidental exposure.